Patents by Inventor Padma MANAM

Padma MANAM has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Isoquinolinyl triazolone complexes
    Patent number: 11786608
    Abstract: Disclosed is a complex of a compound of Formula 1, a stereoisomer thereof, or a tautomer of the compound of Formula 1 or stereoisomer thereof, and a cyclodextrin, in which the complex is an amorphous solid. This disclosure also relates to materials and methods for preparing the complex, to pharmaceutical compositions which contain the complex, and to the use of the complex to treat Type I hypersensitivity reactions, autoimmune diseases, inflammatory disorders, cancer, non-malignant proliferative disorders, and other conditions associated with BTK.
    Type: Grant
    Filed: January 8, 2021
    Date of Patent: October 17, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Rongliang Chen, Padma Manam, Lu Zeng
  • ISOQUINOLINYL TRIAZOLONE COMPLEXES
    Publication number: 20210138086
    Abstract: Disclosed is a complex of a compound of Formula 1, a stereoisomer thereof, or a tautomer of the compound of Formula 1 or stereoisomer thereof, and a cyclodextrin, in which the complex is an amorphous solid. This disclosure also relates to materials and methods for preparing the complex, to pharmaceutical compositions which contain the complex, and to the use of the complex to treat Type I hypersensitivity reactions, autoimmune diseases, inflammatory disorders, cancer, non-malignant proliferative disorders, and other conditions associated with BTK.
    Type: Application
    Filed: January 8, 2021
    Publication date: May 13, 2021
    Inventors: Rongliang Chen, Padma Manam, Lu Zeng
  • ISOQUINOLINYL TRIAZOLONE COMPLEXES
    Publication number: 20190105407
    Abstract: A complex of a compound of Formula 1, a stereoisomer thereof, or a tautomer of the compound of Formula 1 or stereoisomer thereof, and a cyclodextrin, in which the complex is an amorphous solid. This disclosure also relates to materials and methods for preparing the complex, to pharmaceutical compositions which contain the complex, and to the use of the complex to treat Type I hypersensitivity reactions, autoimmune diseases, inflammatory disorders, cancer, non-malignant proliferative disorders, and other conditions associated with BTK.
    Type: Application
    Filed: March 30, 2017
    Publication date: April 11, 2019
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Rongliang CHEN, Padma MANAM, Lu ZENG